Cognitive improvement in schizophrenia with novel antipsychotic medications

Schizophrenia Research

Volumn 35, Issue SUPPL., 1999, Pages

  Purdon, Scot E ^a  

^a ALBERTA HOSPITAL EDMONTON   (Canada)

Author keywords

Clozapine; Cognitive function; Olanzapine; Quetiapine; Risperidone

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COGNITION DISORDERS; DIBENZOTHIAZEPINES; HUMANS; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0033105823     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00166-2     Document Type: Conference Paper

References (42)

1. Bakshi V.P., Swerdlow N.R., Braff D.L., Geyer M.A. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol. Psychiatry. 43:1998;436-445.
2. Beasley C.M., Tollefson G., Tran P.et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
3. Bilder R.M., Turkel E., Lipschutz-Broch L.et al. Antipsychotic medication effects on neuropsychological function. Psychopharmacol. Bull. 28:1992;353-366.
4. Blanchard J.J., Neale J.M. Medication effects: conceptual and methodological issues in schizophrenia research. Clin. Psychol. Rev. 12:1992;345-361.
5. Borison R.L., Arvanitis L.A., Miller B.G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia, U.S. Seroquel Study Group. J. Clin. Psychopharmacol. 16:1996;158-169.
6. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
7. Campbell, D.T., Stanley, J.C., 1963. Experimental and Quasi-Experimental Designs for Research. Houghton Mifflin, Boston.
8. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.B. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 16:1990;477-499.
9. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients (published erratum in J. Clin. Psychopharmacol., April 1993; 13, 149) (see comments). J. Clin. Psychopharmacol. 13:1993;25-40.
10. Classen W., Laux G. Sensorimotor and cognitive performance of schizophrenic patients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry. 21:1988;295-297.
11. Crow T.J. Positive and negative schizophrenia and their response to dopamine. Br. J. Psychiatry. 137:1980;383-386.
12. Crow T.J. The two-syndrome concept: origins and current status. Schizophr. Bull. 11:1985;471-486.
13. Ellenbroek B.A., Lubbers L.J., Cools A.R. Activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology. 15:1996;406-416.
14. Flor-Henry, P., 1983. Cerebral Basis of Psychopathology. John Wright, Boston.
15. Gallhofer B., Bauer U., Lis S., Krieger S., Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur. Neuropsychopharmacol. 6(Suppl. 2):1996;S13-S20.
16. Goldberg T.E., Wienberger D.R., Berman K.F., Pishkin N.H., Podd M. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch. Gen. Psychiatry. 44:1987;1008-1014.
17. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48.
18. Green M.F. Cognitive remediation in schizophrenia: Is it time yet? Am. J. Psychiatry. 150:1993;178-187.
19. Green M.F., Marshall B.D. Jr., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry. 154:1997;799-804.
20. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
21. Heaton, R.K., Crowley, T.J., 1981. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Fisklov, S., Boll, T. (Eds.), Handbook of Clinical Neuropsychology. Wiley, New York, pp. 481-525.
22. Hoff A.L., Faustman W.O., Wieneke M., Espinoza S., Costa M., Wolkowitz O.et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
23. Jaeger J., Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr. Q. 63:1992;71-94.
24. Johnstone E.C., Crow T.J., Frith C.D., Husband J., Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. II:1976;924-926.
25. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., Clozaril Collaborative Study Group, 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789-796.
26. Kolb B., Wishaw I.Q. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J. Nerv. Ment. Dis. 171:1983;435-443.
27. Kraepelin, E., 1919/1971. Dementia Praecox and Paraphrenia (Barclay, R.M., trans.). R. Krieger Publishing, New York.
28. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55:1994;82-87.
29. Medalia A., Gold J., Merriam A. The effects of neuroleptics on neuropsychological test results in schizophrenia. Arch. Clin. Neurology. 3:1988;249-271.
30. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 14(Suppl. 3):1996;27S-33S.
31. Purdon S.E., Lit W., Labelle A., Jones B.D. Risperidone treatment of pervasive developmental disorders. Can. J. Psychiatry. 30:1994;6-11.
32. Purdon, S.E., Canadian Cognition and Outcomes Study Group, 1997. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Schizophr. Res. 29, 152-153.
33. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
34. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
35. Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95:1997;40-43.
36. Schooler, N.R., Hogarty, G.E., Weissman, M.M., 1979. Social Adjustment Scale II (SAS II). In: Hargreaves, W.A., Attkinsson, C.C., Sorenson, J.E. (Eds.), Resource Materials for Community Mental Health Evaluators. DHEW Pub. No. (ADM) 79-328. U.S. Department of Health, Education, and Welfare, Washington, DC, pp. 290-330.
37. Spohn H.E., Strauss M.E. The relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98:1989;367-380.
38. Stip E., Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can. J. Psychiatry. 41(Suppl. 2):1996;S35-S40.
39. Stip E., Lussier I., Babai M., Fabian J.L., Link C. Seroquel and cognitive improvement in patients with schizophrenia. Lett. Biol. Psychiatry. 40:1996;434-435.
40. Swerdlow N.R., Bakshi V., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279:1996;1290-1299.
41. Tomer R., Flor-Henry P. Neuroleptics reverse attention asymmetries in schizophrenic patients. Biol. Psychiatry. 25:1989;852-860.
42. Vahid-Ansari F., Nakabeppu Y., Robertson G.S. Contrasting effects of chronic clozapine, Seroquel (TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain. Eur. J. Neurosci. 8:1996;927-936.